SACUBRIGHT 100 (Sacubitril 49mg, Valsartan 51mg): Uses, Dosage, Key Features, Benefits, and More

SACUBRIGHT 100 Mg

Sacubitril (49mg), Valsartan (51mg)

SACUBRIGHT 100 is a combination medication containing Sacubitril 49mg and Valsartan 51mg. This formulation is used in the management of heart failure with reduced ejection fraction (HFrEF), a condition where the heart's pumping ability is compromised. Let's explore its uses, dosage, key features, benefits, and more.

Uses:

• Heart Failure: SACUBRIGHT 100 is indicated for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in patients who remain symptomatic despite optimal medical therapy. It is used to improve symptoms, reduce the risk of hospitalizations due to heart failure exacerbations, and prolong life expectancy.

Dosage:

• Initial Dose: The recommended starting dose of SACUBRIGHT 100 is one tablet (Sacubitril 49mg, Valsartan 51mg) twice daily. The dosage may be adjusted based on individual response, tolerability, and blood pressure levels.

• Titration: Healthcare providers may titrate the dosage of SACUBRIGHT 100 gradually based on the patient's clinical status, including blood pressure, renal function, and potassium levels. Close monitoring is crucial during dose adjustments.

Key Features and Benefits:

1. Dual Mechanism of Action: SACUBRIGHT 100 combines Sacubitril and Valsartan, which exert complementary effects in managing heart failure. Sacubitril inhibits neprilysin, leading to increased levels of beneficial peptides that promote vasodilation and diuresis, while Valsartan is an angiotensin II receptor blocker (ARB) that blocks the effects of angiotensin II, reducing vasoconstriction and aldosterone release.

2. Symptom Improvement: Clinical studies have shown that SACUBRIGHT 100 significantly improves symptoms of heart failure, such as dyspnea (shortness of breath), fatigue, exercise intolerance, and fluid retention, allowing patients to lead a more active and comfortable life.

3. Reduced Hospitalizations: Treatment with SACUBRIGHT 100 has been associated with a significant reduction in the risk of hospitalizations due to heart failure exacerbations. This leads to improved disease management, decreased healthcare utilization, and better quality of life for patients.

4. Improved Survival: SACUBRIGHT 100 has demonstrated efficacy in prolonging survival and reducing mortality rates in patients with HFrEF, making it a vital component of evidence-based heart failure therapy.

5. Renal Protection: The combination of Sacubitril and Valsartan in SACUBRIGHT 100 may offer renal protection by improving renal hemodynamics, reducing intraglomerular pressure, and preserving kidney function in heart failure patients.

Precautions and Considerations:

• Hypotension Risk: Patients taking SACUBRIGHT 100 may experience hypotension (low blood pressure), especially during initial dose titration or with concomitant use of diuretics. Blood pressure should be monitored regularly, and dosage adjustments may be necessary to prevent symptomatic hypotension.

• Hyperkalemia Monitoring: Close monitoring of serum potassium levels is recommended, particularly in patients at risk of hyperkalemia (elevated potassium levels), such as those with renal impairment or diabetes.

• Drug Interactions: SACUBRIGHT 100 may interact with certain medications, including potassium-sparing diuretics, potassium supplements, nonsteroidal anti-inflammatory drugs (NSAIDs), and lithium. Healthcare providers should be informed of all medications being taken to avoid potential interactions.

• Pregnancy and Lactation: SACUBRIGHT 100 is contraindicated during pregnancy due to potential fetal harm. It is advised to discontinue SACUBRIGHT 100 or choose alternative therapies if pregnancy is detected. Breastfeeding should also be avoided while taking SACUBRIGHT 100.

Conclusion:

SACUBRIGHT 100 (Sacubitril 49mg, Valsartan 51mg) is a potent combination medication for the management of heart failure with reduced ejection fraction (HFrEF). Its dual mechanism of action, including neprilysin inhibition and angiotensin receptor blockade, leads to improved symptoms, reduced hospitalizations, and enhanced survival outcomes in patients with HFrEF. However, careful dosing, monitoring, and consideration of potential drug interactions and precautions are essential for optimizing treatment efficacy and safety. A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  

 For further information: 

 EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

  BUY NOW